Navigation Links
Cornerstone Therapeutics Announces Closing of Chiesi Transaction
Date:7/30/2009

ing our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Item 1A (Risk Factors) of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on May 7, 2009 and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into, except that in particular circumstances as specifically indicated we may address the potential impact of our transaction with Chiesi. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
2. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
5. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
6. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
7. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
8. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
9. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
10. Cell Therapeutics, Inc. Announces Exercise of Overallotment
11. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Calif. , Aug. 28, 2014  Armetheon, ... on developing novel mid- to late-stage cardiovascular drug ... million in its first round of financing. The ... Investments and Hercules Bioventures with participation from investors ... and pharmaceutical executive, Dr. Larry Hsu , ...
(Date:8/28/2014)... A new market research report detailing ... from Strategic Consulting, Inc., the leading information resource ... Review, Fourth Edition: Global Review of Microbiology Testing ... compares microbiology test volumes, market values and methods ... and forecasts future volumes and market values through ...
(Date:8/28/2014)... San Diego, CA (PRWEB) August 28, 2014 ... products, Pipette.com is offering a promotion for ... enables Pipette.com customers to purchase the highest quality ... Centrifuge Tubes are ideal for customers doing chemical, ... benefit lab technicians who are not regularly able ...
(Date:8/27/2014)... 27, 2014 Green & Grow Inc. ... B funding and secured Otter Capital as a significant ... accelerate commercialization of GGI’s Agriplier™ technology, building on recent ... , “Since our first meeting, we have been impressed ... product space,” said Alan Sobba, President and CEO of ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... , , , , , , Multiporator , , , ... , Transfection Protocol , Protocol No. 4308 ... , , , , , ... cell , line), , ...
... , , , Multiporator , , , , , ... Transfection Protocol , Protocol No. 4308 915.039 12/1999 , ... , , , , ... 15, , , ...
... Multiporator , , , , , , , , ... Protocol No. 4308 915.022 11/1999 , , , , , , ... Cell line , COS-7, monkey, kidney, ... Plasmid RSV/lacZ (in bidistilled H 2 O), , , ...
Cached Biology Technology:Jurkat 2Jurkat 3Embryonic stem cells, mouse 2Embryonic stem cells, mouse 3COS-7 2
(Date:8/28/2014)... will be built worldwide by 2050. Many of these ... bring an influx of destructive loggers, hunters and illegal ... a ,global roadmap, for prioritising road building across the ... development and environmental protection. , The map has two ... of ecosystems and a ,road-benefits, layer that estimates the ...
(Date:8/28/2014)... person to alert the world to Global Warming, has ... and stored underground. He says that Carbon Capture, combined ... way to avoid global warming getting out of control ... New York) made the call during his presentation to ... scientists are meeting to discuss Carbon Capture and Storage. ...
(Date:8/28/2014)... (LMU) in Munich have assigned a number of ... arthropods. These animals lived in shallow marine habitats ... found in Jurassic strata. , Before they ... habitat and were fossilized some 435 million years ... the Silurian seas although they were not ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2Paleontology: Oldest representative of a weird arthropod group 2
... not a pregnant woman will give birth to a child with ... is. Although it is a fact that as women get ... Syndrome, other factors also play a role. According to Markus ... and Epidemiology at University Hospital Essen, in Germany, the risk of ...
... technology promises to speed up the accurate sorting of ... and treatment of disease. , Separating proteins from complex ... for understanding diseases and developing new treatments. The molecular ... conventional methods and has the potential to be much ...
... study in Journal of the World Aquaculture Society suggests that, ... same gender when competing for food, male shrimp will almost ... species are typically much smaller than the adult females of ... factors in acquiring food," says study author Dustin Moss, "but ...
Cached Biology News:Down syndrome: It's not just the age factor 2MIT's molecular sieve advances protein research 2
... Aph-1a (Aph-1aL,S Loop 92-115), O2F1 Affinity ... a multiprotein complex consisting of presenilin, ... proteins are necessary for full proteolytic ... cleavage of a number of integral ...
... S-X media are neutral, porous ... exclusion chromatography of lipophilic polymers ... organic eluents. The beads are ... carbon tetrachloride, dimethylformamide, ketones, aromatics, ...
TGase3 (S-20)...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: